These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1982 related articles for article (PubMed ID: 30291106)

  • 1. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
    Diabetes Care; 2018 Dec; 41(12):2669-2701. PubMed ID: 30291106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; D'Alessio DA; Fradkin J; Kernan WN; Mathieu C; Mingrone G; Rossing P; Tsapas A; Wexler DJ; Buse JB
    Diabetologia; 2018 Dec; 61(12):2461-2498. PubMed ID: 30288571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Buse JB; Wexler DJ; Tsapas A; Rossing P; Mingrone G; Mathieu C; D'Alessio DA; Davies MJ
    Diabetes Care; 2020 Feb; 43(2):487-493. PubMed ID: 31857443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
    Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
    Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; Aroda VR; Collins BS; Gabbay RA; Green J; Maruthur NM; Rosas SE; Del Prato S; Mathieu C; Mingrone G; Rossing P; Tankova T; Tsapas A; Buse JB
    Diabetologia; 2022 Dec; 65(12):1925-1966. PubMed ID: 36151309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; Aroda VR; Collins BS; Gabbay RA; Green J; Maruthur NM; Rosas SE; Del Prato S; Mathieu C; Mingrone G; Rossing P; Tankova T; Tsapas A; Buse JB
    Diabetes Care; 2022 Nov; 45(11):2753-2786. PubMed ID: 36148880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of hyperglycaemia of type 2 diabetes. Paradigm change according to the ADA-EASD consensus report 2018].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Dec; 73(12):629-633. PubMed ID: 30570234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Buse JB; Wexler DJ; Tsapas A; Rossing P; Mingrone G; Mathieu C; D'Alessio DA; Davies MJ
    Diabetologia; 2020 Feb; 63(2):221-228. PubMed ID: 31853556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
    Scheen AJ
    Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR; ;
    Diabetes Care; 2012 Jun; 35(6):1364-79. PubMed ID: 22517736
    [No Abstract]   [Full Text] [Related]  

  • 11. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
    Shin JI
    Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do published ADA studies support the ADA-EASD position statement for the management of hyperglycaemia in type 2 diabetics?
    Rimareix F; Bauduceau B
    Ann Endocrinol (Paris); 2013 Jul; 74(3):207-10. PubMed ID: 23747137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of patients with type 2 diabetes at cardiovascular and renal risk : ESC versus ADA-EASD].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2020 Aug; 16(703):1478-1482. PubMed ID: 32852167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
    de Boer IH; Khunti K; Sadusky T; Tuttle KR; Neumiller JJ; Rhee CM; Rosas SE; Rossing P; Bakris G
    Kidney Int; 2022 Nov; 102(5):974-989. PubMed ID: 36202661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 diabetes pharmacotherapy trends in high-risk subgroups.
    Bae J; Liu D; Chinthammit C; Kadziola Z; Boye K; Mather K
    Diabetes Obes Metab; 2022 Jun; 24(6):1166-1171. PubMed ID: 35243741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
    Morillas C
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():49-53. PubMed ID: 28760226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study.
    Goderis G; Vaes B; Mamouris P; van Craeyveld E; Mathieu C
    Exp Clin Endocrinol Diabetes; 2022 Jul; 130(7):447-453. PubMed ID: 34154020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 100.